ZAC1 and SSTR2 Are Downregulated in Non-Functioning Pituitary Adenomas but Not in somatotropinomas

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Vieria Neto, Leonardo ^a,b   Wildemberg, Luiz Eduardo ^a   Colli, Leandro Machado ^c   Kasuki, Leandro ^a   Marques, Nelma Veronica ^a   Moraes, Aline Barbosa ^a   Gasparetto, Emerson L ^a   Takiya, Christina Maeda ^a   Castro, Margaret ^c   Gadelha, Mônica Roberto ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Lagoa Federal Hospital   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P53; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN ZAC 1;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENETIC CORRELATION; GROWTH HORMONE SECRETING ADENOMA; GUS GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONFUNCTIONING PITUITARY ADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PGK1 GENE; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SSTR1 GENE; SSTR2 GENE; SSTR3 GENE; SSTR5 GENE; TBP GENE; TUMOR INVASION; ZAC1 GENE;

ADENOMA; ADULT; AGED; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PITUITARY GLAND; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84884891292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077406     Document Type: Article

References (30)

1. Patel YC, (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198. doi:10.1006/frne.1999.0183. PubMed: 10433861.
2. Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, et al. (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156: 65-74. doi:10.1530/eje.1.02313. PubMed: 17218727.
3. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, et al. (2009) Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94: 1931-1937. doi:10.1210/jc.2008-1826. PubMed: 19293270.
4. Wildemberg LE, Vieira Neto L, Costa DF, Nasciutti LE, Takiya CM, et al. (2012) Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry. J Endocrinol Invest 35: 580-584. PubMed: 21897115.
5. Wildemberg LE, Vieira Neto L, Costa DF, Nasciuti LE, Takiya CM, et al. (2013) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2, expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 36: 38-43. PubMed: 22472799.
6. Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, et al. (2012) Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 98: E66-E71. PubMed: 23118420.
7. Vieira Neto L, Abucham J, Araujo LA, Boguszewski CL, Bronstein MD, et al. (2011) [Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil]. Arq Bras. Endocrinol Metab 55: 725-726.
8. Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, et al. (2009) Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 10: 111-123. doi:10.1007/s11154-008-9107-z. PubMed: 18791829.
9. Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, et al. (2009) Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer 125: 2122-2126. doi:10.1002/ijc.24602. PubMed: 19637311.
10. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, et al. (2006) Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66: 1576-1582. doi:10.1158/0008-5472.CAN-05-1189. PubMed: 16452215.
11. Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, et al. (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97: E1411-E1420. doi:10.1210/jc.2012-1111. PubMed: 22659247.
12. Gadelha MR, Kasuki L, Korbonits M, (2012) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24: 238-246. PubMed: 23270713.
13. Theodoropoulou M, Stalla GK, Spengler D, (2010) ZAC1 target genes and pituitary tumorigenesis. Mol Cell Endocrinol 326: 60-65. doi:10.1016/j.mce.2010.01.033. PubMed: 20117169.
14. Pagotto U, Arzberger T, Theodoropoulou M, Grübler Y, Pantaloni C, et al. (2000) The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res 60: 6794-6799. PubMed: 11156367.
15. Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A, (2004) Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol Oncol 95: 449-455. doi:10.1016/j.ygyno.2004.08.051. PubMed: 15581945.
16. Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, et al. (1999) Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 18: 3979-3988. doi:10.1038/sj.onc.1202933. PubMed: 10435621.
17. Lemeta S, Salmenkivi K, Pylkkänen L, Sainio M, Saarikoski ST, et al. (2006) Frequent loss of heterozygosity at 6q in pheochromocytoma. Hum Pathol 37: 749-754. doi:10.1016/j.humpath.2006.02.002. PubMed: 16733217.
18. Lemeta S, Jarmalaite S, Pylkkänen L, Böhling T, Husgafvel-Pursiainen K, (2007) Preferential loss of the nonimprinted allele for the ZAC1 tumor suppressor gene in human capillary hemangioblastoma. J Neuropathol Exp Neurol 66: 860-867. doi:10.1097/nen.0b013e318149ee64. PubMed: 17805016.
19. Michaelis KA, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards MG, et al. (2011) Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 152: 3603-3613. doi:10.1210/en.2011-0109. PubMed: 21810943.
20. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, et al. (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94: 4406-4413. doi:10.1210/jc.2009-0471. PubMed: 19820025.
21. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, et al. (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82: 818-824. doi:10.1210/jc.82.3.818. PubMed: 9062489.
22. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034. PubMed: 12184808.
23. Pabinger S, Thallinger GG, Snajder R, Eichhorn H, Rader R, et al. (2009) QPCR: Application for real-time PCR data management and analysis. BMC Bioinformatics 10: 268. doi:10.1186/1471-2105-10-268. PubMed: 19712446.
24. Ramakers C, Ruijter JM, Deprez RH, Moorman AF, (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62-66. doi:10.1016/S0304-3940(02)01423-4. PubMed: 12618301.
25. Jomori de Pinho Kasuki L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, et al. (2011) Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94: 39-48. doi:10.1159/000322787. PubMed: 21178332.
26. Bevan JS, (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90: 1856-1863. PubMed: 15613435.
27. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, et al. (2008) Antitumor effects of somatostatin. Mol Cell Endocrinol 286: 230-237. doi:10.1016/j.mce.2008.02.002. PubMed: 18359151.
28. Theodoropoulou M, Barlier A, Pertuit MM, Buchfelder M, Stalla GK, (2012) Regulation of Somatostatin Receptor Type 2 (SSTR2) by the Transcriptional Cofactor ZAC1. J Klin Endokrinol Stoffw 5: 1.
29. Pagotto U, Arzberger T, Ciani E, Lezoualc'h F, Pilon C, et al. (1999) Inhibition of Zac1, a new gene differentially expressed in the anterior pituitary, increases cell proliferation. Endocrinology 140: 987-996. doi:10.1210/en.140.2.987. PubMed: 9927333.
30. Florio T, Morini M, Villa V, Arena S, Corsaro A, et al. (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144: 1574-1584. doi:10.1210/en.2002-220949. PubMed: 12639942.